Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2016.07.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
Transl Cancer Res
November 2024
Section of Urologic Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Background And Objective: A standard of care for muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Given recent improvements in NAC and the morbidity associated with RC, bladder-sparing therapy has been investigated as a promising treatment for patients with MIBC who experience a complete clinical response (CCR) to systemic therapy. However, clinical staging is unreliable, making it challenging to determine ideal candidates for bladder-sparing therapy.
View Article and Find Full Text PDFHow Do I Match? A Survey Study on the Impact of Step 1 Becoming Pass/Fail.
J Surg Educ
November 2024
Division of Urology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Article Synopsis
- Step 1 of the medical licensing exam is now pass/fail (P/F), leading to uncertainty among students about how to enhance their residency applications.
- An electronic survey of 255 medical students showed that while 61.6% preferred the P/F format, those aiming for highly competitive specialties (HCS) favored numerical scoring due to perceived advantages.
- Students expressed concerns that financial resources influence opportunities like research years, benefiting those from prestigious schools and impacting application equity.
National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy.
BJU Int
January 2025
Section of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Objective: To examine the impact of increased compliance to contemporary perioperative care measures, as outlined by enhanced recover after surgery (ERAS) guidelines, among patients undergoing radical cystectomy (RC).
Patients And Methods: From the National Surgical Quality Improvement Program database we captured patients undergoing RC between 2019 and 2021. We identified five perioperative care measures: regional anaesthesia block, thromboembolism prophylaxis, ≤24 h perioperative antibiotic administration, absence of bowel preparation, and early oral diet.
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers.
J Cancer Immunol (Wilmington)
January 2024
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Introduction & Objective: The role of the microbiome in the development and treatment of genitourinary malignancies is just starting to be appreciated. Accumulating evidence suggests that the microbiome can modulate immunotherapy through signaling in the highly dynamic tumor microenvironment. Nevertheless, much is still unknown about the immuno-oncology-microbiome axis, especially in urologic oncology.
View Article and Find Full Text PDFThe Association Between Duration of Antibiotics and Infectious Complications Following Radical Cystectomy: Analysis of the 2019-2021 NSQIP Database.
Urology
July 2024
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Objectives: To identify the impact of the duration of peri-operative antibiotics on infectious complications following radical cystectomy.
Methods: The National Surgical Quality Improvement Project (NSQIP) targeted database was queried for patients undergoing radical cystectomy from 2019 to 2021. Baseline patient characteristics were collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!